Hansen Medical, Inc., a global leader in Intravascular Robotics, today announced it will present its Magellan™ Robotic System at The Society for Vascular Surgery's (SVS) 2014 Vascular Annual Meeting from June 5 - 7 at the Hynes Convention Center in Boston, MA.
The Company will also be conducting product demonstrations with the Magellan Family of Robotic Catheters, including the recently FDA cleared Magellan 6Fr Robotic Catheter at Booth 1115.
In addition, Hansen Medical will feature multiple speakers at its exhibit booth throughout the conference.
- On Thursday, June 5 at 3:30 pm, Alan Lumsden, MD, from Houston Methodist Hospital in Houston, TX will discuss his clinical experiences with the new Magellan 6Fr Robotic Catheter in a talk titled "First Time Every Time: Intravascular Robotics and Advanced 3D Imaging."
- On Friday, June 6, John Matsuura, MD, from Miami Valley Hospital in Dayton, OH will give a talk titled, "Real World Intravascular Robotics Implementation: Clinical Experiences and Lessons Learned". This talk will take place at 9:30am in Exhibit Hall D and at 3:00pm in the Hansen Booth.
- On Friday, June 6 at 12:15 pm, Jean Bismuth, MD, also from Houston Methodist, will present on the hospital's experience with the Magellan Robotic System.
"Hansen is excited to return to SVS for the third consecutive year to showcase the new Magellan 6Fr Robotic Catheter to the broader vascular community," said Chris Lowe, Interim CEO of Hansen Medical. "With the recent FDA 510(k) clearance of this new catheter, our customers can expand their clinical use of the Magellan Robotic System to include procedures in smaller diameter vessels, including a variety of robotic assisted embolization and lower extremity procedures."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver improved predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the U.S. and Europe. The Magellan Robotic System offers several important features including:
- Provides improved predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
- Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
- Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
- Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
- The Magellan 9Fr Robotic Catheter for independent, robotic control of the distal tip of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guidewires.
- The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guidewires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™ Robotic Catheter, Magellan™ 6Fr Robotic Catheter, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan 9Fr Robotic Catheter has undergone both CE marking and 510(k) clearance and is commercially available in the European Union, and the U.S. The Magellan 6Fr Robotic Catheter has undergone 510(k) clearance in the U.S. and is in limited release for the next several months in anticipation of more wide-scale commercially availability later in 2014. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan® and Artisan Extend® Control Catheters are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S., the Company's Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheters are cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the U.S., the Sensei X Robotic Catheter System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.
Source: http://www.hansenmedical.com/